Description:Selonsertib, with the CAS number 1448428-04-3, is a small molecule inhibitor primarily targeting the protein kinase known as apoptosis signal-regulating kinase 1 (ASK1). This compound has garnered attention for its potential therapeutic applications, particularly in the treatment of liver diseases, including nonalcoholic steatohepatitis (NASH) and other fibrotic conditions. Selonsertib functions by modulating cellular stress responses and inflammation, which are critical in the progression of liver fibrosis. The substance is characterized by its specific chemical structure, which includes a unique arrangement of functional groups that contribute to its biological activity. In preclinical and clinical studies, selonsertib has demonstrated the ability to reduce liver inflammation and fibrosis, making it a candidate for further investigation in hepatology. However, as with many investigational drugs, its efficacy and safety profile continue to be evaluated through ongoing research and clinical trials.
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.
